Comprehensive medication guide to Vevye including estimated pricing, availability information, side effects, and how to find it in stock at your local pharmacy.
Estimated Insurance Pricing
$0–$100/month
Estimated Cash Pricing
$59–$1,070/month
Medfinder Findability Score
62/100
Summarize with AI
On this page
Vevye (cyclosporine ophthalmic solution 0.1%) is a prescription eye drop approved by the FDA on May 30, 2023, for the treatment of the signs and symptoms of dry eye disease in adults. It is the first and only cyclosporine-based product with an FDA indication covering both the signs and symptoms of dry eye disease.
Vevye is manufactured by Harrow, Inc. (Nasdaq: HROW) using Novaliq's proprietary EyeSol technology — a water-free, preservative-free semifluorinated alkane (perfluorobutylpentane) solution. This unique formulation dissolves cyclosporine completely without water, eliminating the need for preservatives and improving corneal penetration.
Vevye is not on the FDA's official drug shortage list. It is available through major wholesale distributors McKesson, Cardinal Health, and Cencora, and can be shipped to any retail pharmacy within approximately 24 hours. Access challenges are primarily insurance-related (prior authorization, step therapy), not supply-related.
As of 2025, Vevye is covered by all U.S. Medicaid programs and approximately 60% of commercial insurance plans. It was added to key Medicare Part D formularies (Express Scripts, Cigna, Kaiser Permanente, CVS Caremark) in January 2025. The VEVYE Access for All program (launched March 2025) offers $59 per bottle through specialty pharmacy PhilRx with no prior authorization required.
We have a 99% success rate finding medications, even during nationwide shortages.
Need this medication?
0.1% (1 mg/mL) — ophthalmic solution (eye drops)
One drop in each eye twice daily, approximately 12 hours apart. Each 2 mL bottle provides approximately 30 days of therapy.
Vevye is generally well tolerated. In clinical trials with 738 patients, the most common adverse reactions were:
These were the only adverse reactions identified at a frequency above 1% in clinical trials. Vevye has no boxed warnings and no listed contraindications. Blood concentrations of cyclosporine after topical application were below detectable limits (less than 0.1 ng/mL) in all studied patients, meaning systemic absorption is negligible.
Know what you need? Skip the search.
Generic Cyclosporine 0.05%
Generic form of Restasis; same active ingredient at lower concentration. Most affordable option (~$90/month with GoodRx).
Restasis (cyclosporine 0.05%)
Brand-name cyclosporine emulsion; approved 2002. Generic available. Indicated for increased tear production.
Cequa (cyclosporine 0.09%)
Higher-concentration cyclosporine using nanomicellar technology. Direct Pricing program: $89/month without insurance.
Xiidra (lifitegrast 5%)
Non-cyclosporine option; LFA-1 antagonist mechanism. Indicated for both signs and symptoms of dry eye disease.
Miebo (perfluorohexyloctane)
Water-free drop that stabilizes the tear film lipid layer. Best for evaporative dry eye. Dosed four times daily.
Prefer Vevye? We can find it.
Other ophthalmic medications
minorWait at least 15 minutes between Vevye and any other eye drops to ensure proper absorption of each medication.
Oral cyclosporine (Sandimmune, Neoral)
moderateInform your prescriber if you are taking oral cyclosporine for transplant, rheumatoid arthritis, or psoriasis. While Vevye's systemic absorption is negligible, healthcare providers should be aware of all cyclosporine products being used.
Medications that worsen dry eye
minorAntihistamines, antidepressants (SSRIs, tricyclics), diuretics, beta-blockers, hormone medications, and isotretinoin can worsen dry eye disease and may reduce treatment effectiveness.
Medfinder Editorial Standards
Our medication guides are researched and written to help patients make informed decisions. All content is reviewed for accuracy and updated regularly. Learn more about our standards
ChatGPT
Claude
Perplexity
Grok
Gemini